^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Hepatocellular Cancer
    Drug:Tevimbra (tislelizumab-jsgr) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    BeiGene Press Release
    Title:

    China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma

    Published date:
    06/23/2021
    Excerpt:
    BeiGene, Ltd...today announced that the China National Medical Products Administration (NMPA) has granted its anti-PD-1 antibody tislelizumab approval...conditional approval for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with at least one systemic therapy.
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    JAMA Oncol
    Title:

    Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma

    Published date:
    10/05/2023
    Excerpt:
    In RATIONALE-301, tislelizumab demonstrated OS benefit that was noninferior vs sorafenib, with a higher objective response rate and more durable responses, while median progression-free survival was longer with sorafenib. Tislelizumab demonstrated a favorable safety profile vs sorafenib.
    DOI:
    10.1001/jamaoncol.2023.4003
    Trial ID:
    RATIONALE-301
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    BeiGene Press Release
    Title:

    BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer

    Published date:
    08/09/2022
    Excerpt:
    BeiGene...announced that the global Phase 3 RATIONALE 301 trial with tislelizumab met its primary endpoint of non-inferior Overall Survival (OS) versus sorafenib as a first-line treatment in adult patients with unresectable hepatocellular carcinoma (HCC).
    Trial ID:
    RATIONALE-301